Copyright © 2008 Yuhong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
2. D. J. Mangelsdorf, C. Thummel, M. Beato, et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995. View at Publisher · View at Google Scholar
3. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Publisher · View at Google Scholar
4. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar
5. D. W. Anderson, J. H. Ellenberg, C. M. Leventhal, S. C. Reingold, M. Rodriguez, and D. H. Silberberg, “Revised estimate of the prevalence of multiple sclerosis in the United States,” Annals of Neurology, vol. 31, no. 3, pp. 333–336, 1992. View at Publisher · View at Google Scholar · View at PubMed
6. A. D. Sadovnick and G. C. Ebers, “Epidemiology of multiple sclerosis: a critical overview,” Canadian Journal of Neurological Sciences, vol. 20, no. 1, pp. 17–29, 1993.
7. The IFNB Multiple Sclerosis Study Group, “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis—I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial,” Neurology, vol. 43, no. 4, pp. 655–661, 1993.
8. L. D. Jacobs, D. L. Cookfair, R. A. Rudick, et al., “Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis,” Annals of Neurology, vol. 39, no. 3, pp. 285–294, 1996. View at Publisher · View at Google Scholar · View at PubMed
9. K. P. Johnson, B. R. Brooks, J. A. Cohen, et al., “Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial,” Neurology, vol. 45, no. 7, pp. 1268–1276, 1995.
10. E. Millefiorini, C. Gasperini, C. Pozzilli, et al., “Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome,” Journal of Neurology, vol. 244, no. 3, pp. 153–159, 1997. View at Publisher · View at Google Scholar
11. B. K. Kleinschmidt-DeMasters and K. L. Tyler, “Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis,” The New England Journal of Medicine, vol. 353, no. 4, pp. 369–374, 2005. View at Publisher · View at Google Scholar · View at PubMed
12. A. Langer-Gould, S. W. Atlas, A. J. Green, A. W. Bollen, and D. Pelletier, “Progressive multifocal leukoencephalopathy in a patient treated with natalizumab,” The New England Journal of Medicine, vol. 353, no. 4, pp. 375–381, 2005. View at Publisher · View at Google Scholar · View at PubMed
13. G. Van Assche, M. Van Ranst, R. Sciot, et al., “Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease,” The New England Journal of Medicine, vol. 353, no. 4, pp. 362–368, 2005. View at Publisher · View at Google Scholar · View at PubMed
14. S. D. Miller and W. J. Karpus, “The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases,” Immunology Today, vol. 15, no. 8, pp. 356–361, 1994.
15. G. Chinetti, S. Griglio, M. Antonucci, et al., “Activation of proliferator-activated receptors $\alpha$ and $\gamma$ induces apoptosis of human monocyte-derived macrophages,” The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
16. D. C. Jones, X. Ding, and R. A. Daynes, “Nuclear receptor peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$) is expressed in resting murine lymphocytes. The PPAR$\alpha$ in T and B lymphocytes is both transactivation and transrepression competent,” The Journal of Biological Chemistry, vol. 277, no. 9, pp. 6838–6845, 2002. View at Publisher · View at Google Scholar · View at PubMed
17. R. Cunard, M. Ricote, D. DiCampli, et al., “Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors,” Journal of Immunology, vol. 168, no. 6, pp. 2795–2802, 2002.
18. S. Dubrac, P. Stoitzner, D. Pirkebner, et al., “Peroxisome proliferator-activated receptor-$\alpha$ activation inhibits Langerhans cell function,” Journal of Immunology, vol. 178, no. 7, pp. 4362–4372, 2007.
19. P. R. Devchand, H. Keller, J. M. Peters, M. Vazquez, F. J. Gonzalez, and W. Wahli, “The PPAR$\alpha$-leukotriene ${\text{B}}_4$ pathway to inflammation control,” Nature, vol. 384, no. 6604, pp. 39–43, 1996. View at Publisher · View at Google Scholar · View at PubMed
20. P. Delerive, K. De Bosscher, S. Besnard, et al., “Peroxisome proliferator-activated receptor $\alpha$ negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-$\kappa$B and AP-1,” The Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999. View at Publisher · View at Google Scholar
21. R. Cunard, D. DiCampli, D. C. Archer, et al., “WY14,643, a PPAR$\alpha$ ligand, has profound effects on immune responses in vivo,” Journal of Immunology, vol. 169, no. 12, pp. 6806–6812, 2002.
22. J. W. Lee, P. J. Bajwa, M. J. Carson, et al., “Fenofibrate represses interleukin-17 and interferon-$\gamma$ expression and improves colitis in interleukin-10-deficient mice,” Gastroenterology, vol. 133, no. 1, pp. 108–123, 2007. View at Publisher · View at Google Scholar · View at PubMed
23. D. C. Jones, X. Ding, T. Y. Zhang, and R. A. Daynes, “Peroxisome proliferator-activated receptor $\alpha$ negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation,” Journal of Immunology, vol. 171, no. 1, pp. 196–203, 2003.
24. S. Dasgupta, A. Roy, M. Jana, D. M. Hartley, and K. Pahan, “Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-$\alpha$,” Molecular Pharmacology, vol. 72, no. 4, pp. 934–946, 2007. View at Publisher · View at Google Scholar · View at PubMed
25. W. K. Sumanasekera, E. S. Tien, R. Turpey, J. P. Vanden Heuvel, and G. H. Perdew, “Evidence that peroxisome proliferator-activated receptor $\alpha$ is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2,” The Journal of Biological Chemistry, vol. 278, no. 7, pp. 4467–4473, 2003. View at Publisher · View at Google Scholar · View at PubMed
26. W. K. Sumanasekera, E. S. Tien, J. W. Davis, II, R. Turpey, G. H. Perdew, and J. P. Vanden Heuvel, “Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-$\alpha$ (PPAR$\alpha$) and PPAR$\beta$ activity,” Biochemistry, vol. 42, no. 36, pp. 10726–10735, 2003. View at Publisher · View at Google Scholar · View at PubMed
27. A. Gocke, R. Hussain, L. Ben, P. D. Drew, A. E. Lovett-Racke, and M. K. Racke, “Transcriptional modulation of the immune response by peroxisomal proliferator-activated receptor-$\alpha$ agonists in autoimmune disease,” submitted.
28. G. Pascual, A. L. Fong, S. Ogawa, et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-$\gamma$,” Nature, vol. 437, no. 7059, pp. 759–763, 2005. View at Publisher · View at Google Scholar · View at PubMed
29. N. F. L. Spencer, M. E. Poynter, S.-Y. Im, and R. A. Daynes, “Constitutive activation of NF-$\kappa$B in an animal model of aging,” International Immunology, vol. 9, no. 10, pp. 1581–1588, 1997. View at Publisher · View at Google Scholar
30. P. Delerive, P. Gervois, J.-C. Fruchart, and B. Staels, “Induction of I$\kappa$B$\alpha$ expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-$\alpha$ activators,” The Journal of Biological Chemistry, vol. 275, no. 47, pp. 36703–36707, 2000. View at Publisher · View at Google Scholar · View at PubMed
31. P. Delerive, K. De Bosscher, W. V. Berghe, J.-C. Fruchart, G. Haegeman, and B. Staels, “DNA binding-independent induction of I$\kappa$B$\alpha$ gene transcription by PPAR$\alpha$,” Molecular Endocrinology, vol. 16, no. 5, pp. 1029–1039, 2002. View at Publisher · View at Google Scholar
32. J. H. Lee, E. H. Joe, and I. Jou, “PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia,” NeuroReport, vol. 16, no. 8, pp. 829–833, 2005.
33. E. Selim, J. T. Frkanec, and R. Cunard, “Fibrates upregulate TRB3 in lymphocytes independent of PPAR$\alpha$ by augmenting CCAAT/enhancer-binding protein$\beta$ (C/EBP$\beta$) expression,” Molecular Immunology, vol. 44, no. 6, pp. 1218–1229, 2007. View at Publisher · View at Google Scholar · View at PubMed
34. A. E. Lovett-Racke, R. Z. Hussain, S. Northrop, et al., “Peroxisome proliferator-activated receptor $\alpha$ agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004.
35. S. E. Dunn, S. S. Ousman, R. A. Sobel, et al., “Peroxisome proliferator-activated receptor (PPAR)$\alpha$ expression in T cells mediates gender differences in development of T cell-mediated autoimmunity,” Journal of Experimental Medicine, vol. 204, no. 2, pp. 321–330, 2007. View at Publisher · View at Google Scholar · View at PubMed
36. J. Xu, P. D. Storer, J. A. Chavis, M. K. Racke, and P. D. Drew, “Agonists for the peroxisome proliferator-activated receptor-$\alpha$ and the retinoid X receptor inhibit inflammatory responses of microglia,” Journal of Neuroscience Research, vol. 81, no. 3, pp. 403–411, 2005. View at Publisher · View at Google Scholar · View at PubMed
37. J. Xu, J. A. Chavis, M. K. Racke, and P. D. Drew, “Peroxisome proliferator-activated receptor-$\alpha$ and retinoid X receptor agonists inhibit inflammatory responses of astrocytes,” Journal of Neuroimmunology, vol. 176, no. 1-2, pp. 95–105, 2006. View at Publisher · View at Google Scholar · View at PubMed
38. J. Xu, M. K. Racke, and P. D. Drew, “Peroxisome proliferator-activated receptor-$\alpha$ agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis,” Journal of Neurochemistry, vol. 103, no. 5, pp. 1801–1810, 2007. View at Publisher · View at Google Scholar · View at PubMed